worldwide sites | contact | help | site map | large text versionregular text version

Welcome to Novartis





Focus on the patient, follow the science

We create innovative medicines and prioritize our work based on unmet medical need and strong scientific understanding of disease - not the size of the potential commercial market.

Novartis contribution for Indonesia

NHCR : Novartis (NITD)- Hasanuddin Clinical Research Initiative

For the first time Novartis has established an outreach clinical center in Indonesia, focusing on researched on tropical diseases. NHCR aims to be an effective partnership to drive clinical research in dengue fever and tuberculosis (TB).

The NHCR alliance will provide researchers at NITD direct access to hospitals and patients in a real-life context on a daily basis, and provide a platform to lay the groundwork for the clinical development of new medicines against dengue fever and TB.

The Novartis Institute for Tropical Diseases (NITD) will contribute its broad expertise in all aspects of drug discovery and development, as well as innovative technologies and financial support. NITD will also train and educate young students, post-docs and healthcare staff.

The Medical Faculty of Hasanuddin University is one of the prominent medical schools in Indonesia. The Faculty is located in Makassar, a strategic city and the center for development in the eastern region of Indonesia. The Medical Faculty of Hasanuddin University will establish a clinical research unit devoted to patient studies of new diagnostics, biomarker technologies and novel drug candidates.

Starting 2011, Novartis enhances its partnership with University of Hasanuddin to find a novel drug candidate for tropical diseases (dengue & TB). Since then, the name change to NHCRI (NITD - Hasanuddin University Clinical Research Initiatives)



On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.

Learn more about our company history 

Corporate Citizenship